Sanofi SA (ADR) (SNY) is Upgraded by Exane BNP Paribas to Neutral

Sanofi SA (ADR) (SNY) was Upgraded by Exane BNP Paribas to ” Neutral”. Earlier the firm had a rating of “Underperform ” on the company shares. Exane BNP Paribas advised their investors in a research report released on Sep 13, 2016.

Many Wall Street Analysts have commented on Sanofi SA (ADR). Sanofi SA (ADR) was Upgraded by Berenberg to ” Buy” on Sep 8, 2016.

Sanofi SA (ADR) opened for trading at $38.88 and hit $39.86 on the upside on Monday, eventually ending the session at $39.82, with a gain of 1.61% or 0.63 points. The heightened volatility saw the trading volume jump to 6,991,331 shares. Company has a market cap of $102,505 M.

Sanofi SA is a healthcare company focused on patient needs and engaged in the research development manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals Human Vaccines via Sanofi Pasteur and Animal Health via Merial. The Company invests in emerging markets diabetes solutions vaccines consumer health care animal health genzyme and other products. The emerging markets platform includes products from all three of the Company’s principal activities. Under the Company’s Pharmaceuticals business products are grouped into the key fields of diabetes solutions rare diseases multiple sclerosis oncology thrombosis and cardiovascular disease prevention nephrology and bio-surgery. The Human Vaccines activity is operated through Sanofi Pasteur. The Animal Health activity is carried out through Merial.

Sanofi SA (ADR)

Leave a Reply

Sanofi SA (ADR) - Is it time to Sell?

Top Brokerage Firms are advising their investors on Sanofi SA (ADR). Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.